A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

Sponsor
Novartis Pharmaceuticals (Industry)
Overall Status
Recruiting
CT.gov ID
NCT04971226
Collaborator
(none)
402
Enrollment
69
Locations
2
Arms
85.6
Anticipated Duration (Months)
5.8
Patients Per Site
0.1
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The study is designed to compare the efficacy of asciminib 80 mg QD versus Investigator selected TKI for the treatment of newly diagnosed, previously untreated patients with Ph+ CML-CP. The Investigator selected TKI will be one of the following treatment options for first-line treatment of CML-CP - imatinib 400 mg QD or nilotinib 300 mg BID or dasatinib 100 mg QD or bosutinib 400 mg QD.

Detailed Description

This study is a phase III, multi-center, open-label, randomized study of oral asciminib 80 mg QD versus Investigator selected TKI (imatinib, nilotinib, dasatinib, or bosutinib) in adult patients with newly diagnosed Ph+ CML-CP. All comparator TKIs will be made available, unless not permitted by local regulations or local Health Authority, or not approved for the treatment of CML in the country.

The study is designed to compare the efficacy of asciminib 80 mg QD with Investigator selected TKI for the treatment of newly diagnosed, previously untreated patients with Ph+ CML-CP. The Investigator selected TKI will be one of the treatment options approved by major Health Authorities for first-line treatment of CML-CP - imatinib 400 mg QD or nilotinib 300 mg BID or dasatinib 100 mg QD or bosutinib 400 mg QD.

Approximately 402 patients will be randomized in a 1:1 ratio to asciminib and Investigator selected TKI.

Randomization will be stratified based on the following two stratification factors:
  • ELTS score (low versus intermediate versus high)

  • Pre-randomization selected TKI (imatinib versus 2G TKI (nilotinib or dasatinib or bosutinib)).

Prior to randomization, the Investigator, in consultation with the patient, considering the current treatment paradigm and patient characteristics and comorbidities, will make a selection of preference for imatinib or 2G TKI (nilotinib or dasatinib or bosutinib) if the patient is randomized to the comparator arm.

To further ensure that the distribution of patients, between imatinib and 2G TKIs (nilotinib or dasatinib or bosutinib), in the Investigator selected TKI arm is reflective of the use of these agents in clinical practice, the enrollment into the strata of imatinib versus 2G TKI (nilotinib or dasatinib or bosutinib) based on the pre-randomization selection of TKI will be managed by Interactive Response Technology to be approximately 50% versus 50%.

Treatment arms: The study will have 2 treatment arms:
  • Arm 1: asciminib 80 mg QD under fasting conditions

  • Arm 2: Investigator selected TKI that will include one of the below treatments:

  • Imatinib 400 mg QD administered with food

  • Nilotinib 300 mg BID administered under fasting conditions

  • Dasatinib 100 mg QD administered with or without meal

  • Bosutinib 400 mg QD administered with food.

No crossover of study treatment across arms and no change of study treatment within the Investigator selected TKI will be allowed.

Duration of Study treatment: Patients on the study will continue to receive the assigned treatment until the End of Study, or until premature discontinuation due to treatment failure, disease progression or intolerance or due to Investigator or participant decision.

Duration of study: The End of Study will occur 5 years from the last patient first treatment in the study. Patients who discontinue study treatment prematurely due to any reason, will be followed up for survival and progression (to AP/BC) until the End of Study.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
402 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
A Phase III, Multi-center, Open-label, Randomized Study of Oral Asciminib Versus Investigator Selected TKI in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase
Actual Study Start Date :
Oct 6, 2021
Anticipated Primary Completion Date :
Sep 27, 2024
Anticipated Study Completion Date :
Nov 24, 2028

Arms and Interventions

ArmIntervention/Treatment
Experimental: Asciminib

Patients will take asciminib 80 mg QD under fasting conditions on ongoing basis; Patients will be randomized 1:1 asciminib versus Investigator selected TKIs

Drug: Asciminib
Comes in 40 mg tablets and taken orally
Other Names:
  • ABL001
  • Active Comparator: Investigator selected TKIs

    Patients will take on ongoing basis the Investigator selected TKIs that will include one of the below treatments: Imatinib 400 mg QD administered with food Nilotinib 300 mg BID administered under fasting conditions Dasatinib 100 mg QD administered with or without a meal Bosotunib 400 mg QD administered with food

    Drug: Imatinib
    Comes in 100 mg and 400 mg tablets and taken orally
    Other Names:
  • STI571
  • Drug: Nilotinib
    Comes in 150 mg capsules and taken orally
    Other Names:
  • AMN107
  • Drug: Bosutinib
    Comes in 100 mg and 400 mg tablets and taken orally

    Drug: Dasatinib
    Comes in 70 mg and 100 mg tablets and taken orally

    Outcome Measures

    Primary Outcome Measures

    1. Major Molecular Response (MMR) at week 48 [at 48 weeks (48 weeks after last patient first dose)]

      Molecular response is assessed using BCR-ABL transcript levels measured by realtime quantitative polymerase chain reaction. MMR is defined as a ratio BCR-ABL/ABL ≤0.1% on the international scale (ie, at least 3 log reduction from a standardized baseline value).

    Secondary Outcome Measures

    1. Major Molecular response at week 96 [at 96 weeks (96 weeks after last patient first dose)]

      Molecular response is assessed using BCR-ABL transcript levels measured by realtime quantitative polymerase chain reaction. MMR is defined as a ratio BCR-ABL/ABL ≤0.1% on the international scale (ie, at least 3 log reduction from a standardized baseline value).

    2. Time to discontinuation of study treatment due to Adverse Events (TTDAE) [96 weeks after last patient first dose]

      TTDAE is defined as the time from the date of first dose of study treatment to the date of discontinuation of study treatment due to Adverse Event (AE). For patients ongoing without study treatment discontinuation, on or prior to the analysis cut-off date, the time will be censored at the at the analysis cut-off date.

    3. Major Molecular response at scheduled data collection time points [Planned total follow-up duration of 5 years]

      Molecular response is assessed using BCR-ABL transcript levels measured by realtime quantitative polymerase chain reaction. MMR is defined as a ratio BCR-ABL/ABL ≤0.1% on the international scale (ie, at least 3 log reduction from a standardized baseline value).

    4. Major Molecular response by scheduled data collection time points [Planned total follow-up duration of 5 years]

      Molecular response is assessed using BCR-ABL transcript levels measured by realtime quantitative polymerase chain reaction. MMR is defined as a ratio BCR-ABL/ABL ≤0.1% on the international scale (ie, at least 3 log reduction from a standardized baseline value).

    5. MR4.0 at scheduled data collection time points [Planned total follow-up duration of 5 years]

      Molecular response is assessed using BCR-ABL transcript levels measured by realtime quantitative polymerase chain reaction. MR4.0 is defined as a ratio BCR-ABL/ABL ≤0.01% on the international scale (ie, at least 4 log reduction from a standardized baseline value).

    6. MR4.5 at all scheduled data collection time points [Planned total follow-up duration of 5 years]

      Molecular response is assessed using BCR-ABL transcript levels measured by realtime quantitative polymerase chain reaction. MR4.5 is defined as a ratio BCR-ABL/ABL ≤0.0032% on the international scale (ie, at least 4.5 log reduction from a standardized baseline value).

    7. MR4.0 by scheduled data collection time points [Planned total follow-up duration of 5 years]

      Molecular response is assessed using BCR-ABL transcript levels measured by realtime quantitative polymerase chain reaction. MR4.0 is defined as a ratio BCR-ABL/ABL ≤0.01% on the international scale (ie, at least 4 log reduction from a standardized baseline value).

    8. MR4.5 by all scheduled data collection time points [Planned total follow-up duration of 5 years]

      Molecular response is assessed using BCR-ABL transcript levels measured by realtime quantitative polymerase chain reaction. MR4.5 is defined as a ratio BCR-ABL/ABL ≤0.0032% on the international scale (ie, at least 4.5 log reduction from a standardized baseline value).

    9. Complete Hematological response (CHR) at all scheduled data collection time points [Planned total follow-up duration of 5 years]

      Hematologic response will be assessed by CBC and physical examination at each visit. Complete Hematological Response (CHR) will be defined as all of the following present for ≥ 4 weeks: white blood cell(s) (WBC) count < 10 x 10^9/L PLT count < 450 x 10^9/L Basophils < 5% No blasts and promyelocytes in peripheral blood Myelocytes + metamyelocytes < 5% in peripheral blood No evidence of extramedullary disease, including spleen and liver

    10. Complete Hematological response (CHR) by all scheduled data collection time points [Planned total follow-up duration of 5 years]

      Hematologic response will be assessed by CBC and physical examination at each visit. Complete Hematological Response (CHR) will be defined as all of the following present for ≥ 4 weeks: white blood cell(s) (WBC) count < 10 x 10^9/L PLT count < 450 x 10^9/L Basophils < 5% No blasts and promyelocytes in peripheral blood Myelocytes + metamyelocytes < 5% in peripheral blood No evidence of extramedullary disease, including spleen and liver

    11. Complete Cytogenic response (CCyR) at Week 48 & Week 96 [at 48 weeks and at 96 weeks (48 weeks and 96 weeks after last patient first dose)]

      The CCyR response status will be based on the BCR-ABL1 levels measured in peripheral blood by realtime PCR. A BCR-ABL1 (IS) level of <1% is considered equivalent to CCyR

    12. Complete Cytogenic response (CCyR) by Week 48 & Week 96 [at 48 weeks and at 96 weeks (48 weeks and 96 weeks after last patient first dose)]

      The CCyR response status will be based on the BCR-ABL1 levels measured in peripheral blood by realtime PCR. A BCR-ABL1 (IS) level of <1% is considered equivalent to CCyR

    13. Duration of MMR [Planned total follow-up duration of 5 years]

      Duration of MMR is defined as the time between the date of the first documented achievement of MMR and the earliest date of loss of MMR, treatment failure, progression to Accelerated Phase/Blast Crisis, or CML-related death

    14. Duration of MR4.0 [Planned total follow-up duration of 5 years]

      Duration of MR4.0 is defined as the time between the date of the first documented achievement of MR4.0 and the earliest date of loss of MR4.0, treatment failure, progression to Accelerated Phase/Blast Crisis, or CML-related death

    15. Duration of MR4.5 [Planned total follow-up duration of 5 years]

      Duration of MR4.5 is defined as the time between the date of the first documented achievement of MR4.5 and the earliest date of loss of MR4.5, treatment failure, progression to Accelerated Phase/Blast Crisis, or CML-related death

    16. Time to first MMR [Planned total follow-up duration of 5 years]

      Time to first MMR is defined as the time from the date of randomization to the date of the first documented occurrence of MMR. Time will be censored at the last molecular assessment date while on treatment, or the End Of Treatment (whichever comes first) for patients who have not experienced MMR.

    17. Time to first MR4.0 [Planned total follow-up duration of 5 years]

      Time to first MR4.0 is defined as the time from the date of randomization to the date of the first documented occurrence of MR4.0. Time will be censored at the last molecular assessment date while on treatment, or the End Of Treatment (whichever comes first) for patients who have not experienced MR4.0.

    18. Time to first MR4.5 [Planned total follow-up duration of 5 years]

      Time to first MR4.5 is defined as the time from the date of randomization to the date of the first documented occurrence of MR4.5. Time will be censored at the last molecular assessment date while on treatment, or the End Of Treatment (whichever comes first) for patients who have not experienced MR4.5.

    19. Time to treatment failure (TTF) [Planned total follow-up duration of 5 years]

      TTF is defined as the time from date of randomization to the first/earliest documented date of any of the following events: treatment failure as per ELN, Confirmed loss of MMR while on study treatment, discontinuation from study treatment due to any reason For patients that have not experienced an event prior to or at the analysis cut-off date, the time will be censored at the last study assessment date while on treatment, or the EOT (whichever comes first) .

    20. Failure Free Survival (FFS) [Planned total follow-up duration of 5 years]

      FFS is defined as the time from the date of randomization to the earliest occurrence of the following events: treatment failure per ELN, confirmed loss of MMR, progression to AP/BC, death from any cause. For patients that have not experienced an event prior to or at the analysis cut-off date, the time will be censored at the date of last study treatment assessment or last post-treatment follow-up.

    21. Event Free Survival (EFS) [Planned total follow-up duration of 5 years]

      EFS is defined as the time from the date of randomization to the earliest occurrence of the following events: treatment failure as per ELN, confirmed loss of MMR ,discontinuation of study treatment due to AE, progression to AP/BC, death from any cause. For patients that have not experienced an event prior to or at the analysis cut-off date, the time will be censored at the date of last study treatment assessment or last post-treatment follow-up.

    22. Progression Free Survival (PFS) [Planned total follow-up duration of 5 years]

      PFS is defined as the time from the date of randomization to the earliest occurrence of progression to AP/BC or death from any cause. For patients that have not experienced an event prior to or at the analysis cut-off date, the time will be censored at the date of last study treatment assessment or last post-treatment follow-up.

    23. Overall Survival (OS) [Planned total follow-up duration of 5 years]

      OS is defined as the time from the date of randomization to the date of death from any cause. For patients that have not experienced an event prior to or at the analysis cut-off date, the time will be censored at the date of last contact before the cut-off date.

    24. Trough plasma concentrations. [48 weeks after last patient first dose]

      Trough plasma concentration will measure the concentration of asciminib in the blood immediately before the next dose is administered.

    25. Pharmacokinetics (PK) of Asciminib: Cmax [48 weeks after last patient first dose]

      Cmax is the maximum serum concentration of asciminib during a dosing interval (mass x volume-1).

    26. PK of Asciminib: Tmax [48 weeks after last patient first dose]

      Tmax is the time to reach maximum (peak) plasma drug concentration after dose administration (time)

    27. PK of Asciminib: AUCtau and AUClast [48 weeks after last patient first dose]

      AUCtau is the area under the plasma concentration-time curve over the dosing interval. AUClast is the area under the plasma concentration-time curve from time zero (time of dose administration) to time of last measurable concentration (mass x time x volume-1)

    28. PK of Asciminib: CL/F [48 weeks after last patient first dose]

      CL/F is the apparent total body clearance of asciminib from plasma after oral administration (volume x time-1).

    29. Change from baseline in overall scores and individual scales of the EORTC QLQ-C30 [baseline, 48 weeks after last patient first dose, 96 weeks after last patient first dose]

      The European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-30) consists of functioning scales, symptoms' scales, single-item scales and the global health status quality of life (QoL) scale. A high score for functional and QoL items/scales from the QLQ-30 represents better function and QOL. A high score in symptoms items from QLQ-30 represents worse symptoms.

    30. Change from baseline in overall scores and individual scales of the EORTC QLQ-CML24 [baseline, 48 weeks after last patient first dose, 96 weeks after last patient first dose]

      The QLQ-CML24 consists of (i) 22 multi-scale items: impact on daily life, symptom burden, impact on worry/mood, satisfaction with care and information, (ii) 2 single items: body image problems, and satisfaction with social life. A higher score on most of the item scales in QLQ-CML24 reflects a larger impairment in the corresponding domain, with the exception of the satisfaction with care and information, and problems and satisfaction with social life, where a higher score reflects a higher level of satisfaction.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Participants eligible for inclusion in this study must meet all of the following criteria:
    1. Male or female patients ≥ 18 years of age.

    2. Patients with CML-CP within 3 months of diagnosis.

    3. Diagnosis of CML-CP with cytogenetic confirmation of Philadelphia chromosome of (9;22) translocations (presence of BCR-ABL1 in a review of a minimum 20 metaphases is required).

    • Documented chronic phase CML will meet all the below criteria Hochhaus et al 2020:

    • < 15% blasts in peripheral blood and bone marrow,

    • < 30% blasts plus promyelocytes in peripheral blood and bone marrow,

    • < 20% basophils in the peripheral blood,

    • Platelet count ≥ 100 x 109/L (≥ 100,000/mm3),

    • No evidence of extramedullary leukemic involvement, with the exception of hepatosplenomegaly.

    1. Eastern Cooperative Oncology Group (ECOG) performance status of 0,or 1. 5.
    Adequate end organ function as defined by:
    • Total bilirubin < 3 x ULN; patients with Gilbert's syndrome may only be included if total bilirubin ≤ 3.0 x ULN or direct bilirubin ≤ 1.5 x ULN

    • Creatinine clearance (ClCr) ≥ 30 mL/min as calculated using Cockcroft-Gault formula,

    • Serum lipase ≤ 1.5 x ULN. For serum lipase > ULN - ≤ 1.5 x ULN, value must be considered not clinically significant and not associated with risk factors for acute pancreatitis 6. Patients must have the following laboratory values ≥ LLN or corrected to within normal limits with supplements prior to randomization:

    • Potassium (potassium increase of up to 6.0 mmol/L is acceptable if associated with ClCr* ≥ 90 mL/min)

    • Total calcium (corrected for serum albumin); (calcium increase of up to 12.5 mg/dl or 3.1 mmol/L is acceptable if associated with ClCr* ≥ 90 mL/min)

    • Magnesium (magnesium increase of up to 3.0 mg/dL or 1.23 mmol/L if associated with ClCr* ≥ 90 mL/min)

    • For patients with mild to moderate renal impairment (ClCr* ≥ 30 mL/min and <90 mL/min) - potassium, total calcium (corrected for serum albumin) and magnesium should be ≥ LLN or corrected to within normal limits with supplements prior to randomization.

    • *ClCr as calculated using Cockcroft-Gault formula 7. Ability to provide written informed consent prior to any study related screening procedures being performed.

    1. Evidence of typical BCR-ABL1 transcript [e14a2 and/or e13a2] at the time of screening which is amenable to standardized Real time quantitative polymerase chain reaction (RQ-PCR) quantification.
    Exclusion Criteria:
    1. Previous treatment of CML with any other anticancer agents including chemotherapy and/or biologic agents or prior stem cell transplant, with the exception of hydroxyurea and/or anagrelide. Treatment with imatinib for ≤2 weeks is allowed, but no other treatment with tyrosine kinase inhibitors prior to study entry is permitted.

    2. Known cytopathologically confirmed CNS infiltration (in absence of suspicion of CNS involvement, lumbar puncture not required).

    3. Impaired cardiac function or cardiac repolarization abnormality including but not limited to any one of the following:

    • History within 6 months prior to starting study treatment of myocardial infarction (MI), angina pectoris, coronary artery bypass graft (CABG)

    • Clinically significant cardiac arrhythmias (e.g., ventricular tachycardia), complete left bundle branch block, high-grade AV block (e.g., bifascicular block, Mobitz type II and third degree AV block)

    • QTc ≥ 450 msec (male patients), ≥460 msec (female patients) on the average of three serial baseline ECG (using the QTcF formula) as determined by central reading. If QTcF ≥ 450 msec and electrolytes are not within normal ranges, electrolytes should be corrected and then the patient re-screened for QTc.

    • Long QT syndrome, family history of idiopathic sudden death or congenital long QT syndrome, or any of the following:

    • Risk factors for Torsades de Pointes (TdP) including uncorrected hypokalemia or hypomagnesemia, history of cardiac failure, or history of clinically significant/symptomatic bradycardia

    • Concomitant medication(s) with a "Known risk of Torsades de Pointes" per www.crediblemeds.org/ that cannot be discontinued or replaced 7 days prior to starting study drug by safe alternative medication.•Inability to determine the QTcF interval

    1. Severe and/or uncontrolled concurrent medical disease that in the opinion of the investigator could cause unacceptable safety risks or compromise compliance with the protocol (e.g. uncontrolled diabetes, active or uncontrolled infection; uncontrolled arterial or pulmonary hypertension, uncontrolled clinically significant hyperlipidemia). Please refer to Section 6.3.1

    2. History of significant congenital or acquired bleeding disorder unrelated to cancer.

    3. Major surgery within 4 weeks prior to study entry or who have not recovered from prior surgery.

    4. History of other active malignancy within 3 years prior to study entry with the exception of previous or concomitant basal cell skin cancer and previous carcinoma in situ treated curatively

    5. History of acute pancreatitis within 1 year prior to randomization or medical history of chronic pancreatitis.

    6. History of chronic liver disease leading to severe hepatic impairment, or ongoing acute liver disease.

    Other protocol-defined Inclusion/exclusion criteria will apply.

    Contacts and Locations

    Locations

    SiteCityStateCountryPostal Code
    1Rocky Mountain Cancer CentersDenverColoradoUnited States80501
    2Illinois Cancer Care P.C. IL Cancer SpecialistsPeoriaIllinoisUnited States61615-7828
    3Oncology Hematology Care IncCincinnatiOhioUnited States45242
    4Williamette Cancer CenterEugeneOregonUnited States97401
    5Chattanooga Oncology and Hematology Associates PC Tennessee Oncology ChattanoogaChattanoogaTennesseeUnited States37404
    6Texas Oncology Texas Onc - AmarilloDallasTexasUnited States75246
    7Texas Oncology-Baylor USODallasTexasUnited States75246
    8Texas Oncology P A AustinDallasTexasUnited States75251
    9US Oncology P ATylerTexasUnited States75702
    10Virginia Cancer SpecialistsGainesvilleVirginiaUnited States20155
    11Virginia Oncology AssociatesNorfolkVirginiaUnited States23502
    12Novartis Investigative SiteKingswoodNew South WalesAustralia2747
    13Novartis Investigative SitePort MacquarieNew South WalesAustralia2444
    14Novartis Investigative SiteWoolloongabbaQueenslandAustralia4102
    15Novartis Investigative SiteLinzUpper AustriaAustria4010
    16Novartis Investigative SiteWienAustria1090
    17Novartis Investigative SiteHamiltonOntarioCanadaL8V 1C3
    18Novartis Investigative SiteTorontoOntarioCanadaM5G 2M9
    19Novartis Investigative SiteShenzhenGuangdongChina518037
    20Novartis Investigative SiteNantongJiangsuChina226000
    21Novartis Investigative SiteChengduSichuanChina610041
    22Novartis Investigative SiteTianjinTianjinChina300020
    23Novartis Investigative SiteBrno BohuniceCzech RepublicCzechia625 00
    24Novartis Investigative SiteOstrava PorubaCzech RepublicCzechia708 52
    25Novartis Investigative SiteHradec KraloveCZECzechia500 05
    26Novartis Investigative SiteHelsinkiFinlandFIN 00290
    27Novartis Investigative SiteBordeauxFrance33076
    28Novartis Investigative SiteLyon CedexFrance69373
    29Novartis Investigative SiteNantes Cedex 1France44093
    30Novartis Investigative SiteParis Cedex 10France75475
    31Novartis Investigative SiteMannheimBaden-WuerttembergGermany68305
    32Novartis Investigative SiteAachenGermany52074
    33Novartis Investigative SiteBerlinGermany13353
    34Novartis Investigative SiteFrankfurtGermany60590
    35Novartis Investigative SiteJenaGermany07740
    36Novartis Investigative SiteLuebeckGermany23538
    37Novartis Investigative SiteDebrecenHungary4032
    38Novartis Investigative SiteKaposvarHungary7400
    39Novartis Investigative SiteKecskemetHungary6001
    40Novartis Investigative SiteDelhiIndia110 085
    41Novartis Investigative SiteVeronaVRItaly37126
    42Novartis Investigative SiteToyoake cityAichiJapan470 1192
    43Novartis Investigative SiteFukushima cityFukushimaJapan960 1295
    44Novartis Investigative SiteAkitaJapan010-8543
    45Novartis Investigative SiteYamagataJapan990 9585
    46Novartis Investigative SiteUijeongbu siGyeonggi DoKorea, Republic of11759
    47Novartis Investigative SiteSeoulKorea, Republic of03080
    48Novartis Investigative SiteSeoulKorea, Republic of03722
    49Novartis Investigative SiteSeoulKorea, Republic of06351
    50Novartis Investigative SiteKuantanPahangMalaysia25100
    51Novartis Investigative SiteSubang JayaSelangorMalaysia47500
    52Novartis Investigative SitePulau PinangMalaysia10990
    53Novartis Investigative SiteSelangorMalaysia68000
    54Novartis Investigative SiteOsloNorway0372
    55Novartis Investigative SiteTrondheimNorway7006
    56Novartis Investigative SiteMoscowRussian Federation127644
    57Novartis Investigative SiteSaint PetersburgRussian Federation191024
    58Novartis Investigative SiteSingaporeSingapore119228
    59Novartis Investigative SiteSingaporeSingapore169608
    60Novartis Investigative SiteBratislavaSlovak RepublicSlovakia83310
    61Novartis Investigative SiteKosiceSlovak RepublicSlovakia040 66
    62Novartis Investigative SiteGranadaAndaluciaSpain18014
    63Novartis Investigative SiteBarcelonaCatalunyaSpain08036
    64Novartis Investigative SiteEl PalmarMurciaSpain30120
    65Novartis Investigative SitePamplonaNavarraSpain31008
    66Novartis Investigative SiteMadridSpain28046
    67Novartis Investigative SiteBellinzonaSwitzerland6850
    68Novartis Investigative SiteTaichungTaiwan40447
    69Novartis Investigative SiteLondonUnited KingdomW12 0NN

    Sponsors and Collaborators

    • Novartis Pharmaceuticals

    Investigators

    • Study Director: Novartis Pharmaceuticals, Novartis Pharmaceuticals

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Novartis Pharmaceuticals
    ClinicalTrials.gov Identifier:
    NCT04971226
    Other Study ID Numbers:
    • CABL001J12301
    • 2021-000678-27
    First Posted:
    Jul 21, 2021
    Last Update Posted:
    Mar 31, 2022
    Last Verified:
    Mar 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    Yes
    Plan to Share IPD:
    Yes
    Studies a U.S. FDA-regulated Drug Product:
    Yes
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Novartis Pharmaceuticals
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Mar 31, 2022